Lumibird Medical announces Asia-Pacific acquisition
The European leader in laser technology has announced the signing of an agreement to acquire its long-standing partner BIZ MEDIC SDN BHD. This transaction aims to transform the group's distribution model in Malaysia into a direct growth engine within a region of high ophthalmological potential.
By integrating Kuala Lumpur-based BIZ MEDIC, Lumibird Medical marks the future creation of Lumibird Medical Southeast Asia. This new hub will allow the group to transition from a third-party distribution model to a direct subsidiary presence. This structural shift is accompanied by geographical streamlining: the centralization of operations in Kuala Lumpur will lead to the closure of the sales office in Thailand and the subsidiary in India.
Targeting a market with high clinical demand
Southeast Asia represents a major demographic opportunity for Lumibird, as the region exhibits some of the highest rates of myopia, glaucoma, and retinal diseases in the world. Jean-Marc Gendre, CEO of the Medical division, emphasized: "Southeast Asia is not just a growth market; it is the most populous region with the most significant needs in ophthalmology."
Toward a unified brand
The future hub's mission will be to organize the distribution of products from the Quantel Medical, Optotek Medical, and Ellex brands. This strategy aims to provide direct clinical support to local hospitals and surgeons while simplifying the management of regional regulatory requirements.
A period of strategic review for the group
While Lumibird Medical accelerates its international expansion, the Lumibird Group specifies that it continues to explore the potential sale of its medical division. The outcome of this strategic review remains, to date, uncertain.
The completion of the BIZ MEDIC acquisition is expected in the coming months, subject to local regulatory approvals.
Lumibird is one of the world's leading laser specialists. With over 50 years' experience and expertise in solid-state, diode and fibre laser technologies, Lumibird designs, manufactures and distributes high-performance laser solutions via two divisions: Photonics and Medical. The Photonics Division designs and produces components, lasers and systems for the defence and space, environment, topography and security, industrial and scientific, and medtech markets. The Medical branch designs and produces medical diagnostic and treatment systems for ophthalmology.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
